About Ginkgo Bioworks
Ginkgo Bioworks is a publicly listed company based in Boston (United States) founded in 2008 by Austin Che, Tom Knight, Barry Canton, Jason Kelly, and Reshma Shetty. Gene editing-based cultured ingredients are provided for agriculture. It operates in the Healthcare and Agriculture sectors. Ginkgo Bioworks has raised $795.75 million across 23 funding rounds from investors including Illumina, Gates and T. Rowe Price. The company has 638 employees. Ginkgo Bioworks has completed 12 acquisitions, including Altar, Beacon Testing and Bitome. Ginkgo Bioworks was last valued at $22 billion in September 2025. Its chief executive, as recorded, is Jason Kelly. Its website ginkgobioworks.com draws about 11 thousand monthly visits. Ginkgo Bioworks offers products and services including AI Models, Data Generation, and Lab Automation. Its focus areas include Life Sciences, Genomics, Applied Genomics and Synthetic Biology. Its competitors include Amyris, Pivot Bio and Asimov; 3 of its 3 listed competitors have raised funding.
Company details
Ginkgo Bioworks was founded in 2008 in Boston, United States. Operations focus on the biotechnology sector, where gene editing technologies are applied to develop cultured ingredients for agriculture. Microbes are engineered and produced to create products including flavors, fragrances, cosmetics, and sweeteners. Services extend to supporting industrial applications through synthetic biology methods.
- Headquarters Boston, United States
- Employees 638
- Founders Austin Che, Tom Knight, Barry Canton, Jason Kelly, Reshma Shetty
- Stage Public
- SectorsHealthcareAgriculture
- Email••••••••
- Phone•••• ••••
- Website ginkgobioworks.com
- Social LinkedIn X Facebook
- Legal Name Ginkgo Bioworks Holdings, Inc.
Products & Services of Ginkgo Bioworks
Ginkgo Bioworks offers a comprehensive portfolio of products and services, including AI Models, Data Generation, and Lab Automation.
AI models for enhancing research and development projects
Tools for creating high-quality datasets in biotech applications
Systems for scalable lab processes in scientific research
Funding Insights of Ginkgo Bioworks
Ginkgo Bioworks has successfully raised a total of $795.75M across 23 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $795.75M
- Total Rounds 23
- First Round $99,981
(Jun 2009)
- Investors Count 50
Latest 10 of 23 funding rounds of Ginkgo Bioworks with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | Grant | – | – | ||
| Aug 2023 | $387,472 | Grant | – | – | |
| Jun 2023 | $649,992 | Grant | – | – | |
| May 2020 | $70M | Series E | – | Illumina | |
| Sep 2019 | $290M | Series E | $4.2B | T. Rowe Price | |
| Dec 2017 | $275M | Series D | – | Viking Global Investors | |
| Jun 2016 | $100M | Series C | – | – | |
| Jul 2015 | $51.63M | Series B | – | Viking Global Investors | |
| Mar 2015 | $9M | Series A | – | Felicis Ventures, DCVC | – |
| Jan 2015 | $179,999 | Grant | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Sep 2019 | $4.2B | •••••••• |
Full valuation and stage history of Ginkgo Bioworks
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $22B (Sep 2025). 50 investors in total: 47 institutional and 3 angel.
Investors in Ginkgo Bioworks
Ginkgo Bioworks has secured backing from 50 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Illumina, Gates and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund focused on global markets | 1980 | generalatlantic.com | New York, United States | |
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States | ||
Private equity & fixed income investments focused hedge fund | senatorlp.com | New York, United States | ||
Early-stage centric sector-agnostic VC firm investing in geographies such as the US | osfund.co | Chicago, United States | ||
Investments in technology startups are made by Felicis Ventures. | felicis.com | Menlo Park, United States | ||
Venture capital firm focused on multiple sectors | dcvc.com | Palo Alto, United States | ||
Tech and life Science focused early stage VC firm investing in the US | iglobepartners.com | Singapore, Singapore | ||
US focused venture capital firm | vastvc.com | New York, United States | ||
Chinese venture fund in Silicon Valley | tsvcap.com | Los Altos, United States |
Investor details for Ginkgo Bioworks
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ginkgo Bioworks
236 people are tracked at Ginkgo Bioworks (82 in leadership, 4 in board & advisors, 150 in team); the tracked headcount is 638.
| Name | Role | Group |
|---|---|---|
Austin Che | Co-Founder | Leadership |
Tom Knight | Co-Founder | Leadership |
Barry Canton | Founder | Leadership |
Jason Kelly | Co-Founder & CEO | Leadership |
Reshma Shetty | Co-Founder | Leadership |
Adam Bargar | Director, Program Finance | Leadership |
Michael Mashock | Associate Director, Lab Enablement | Leadership |
Michael Torrens-Spence | Associate Technical Director, Microbial Engineering (soe2) | Leadership |
Arthur Fong III | Associate Director, Business Operations And Strategy | Leadership |
Kent Wilson | Associate Director Business Development | Leadership |
Cornelis Mijnders | VP, Business Development | Leadership |
Kevin Wright | VP, Continuous Improvement & Industrial Engineering | Leadership |
Dominik Satory | Director, Microbial Engineering | Leadership |
Ryan McCann | Head Of Microbiology | Leadership |
Ariel Hecht | Director Of Microbial Assay Development | Leadership |
Kendrick Goss | Director, Senior Mammalian Engineer III | Leadership |
Swaminath Srinivas | Director - Organism Engineering | Leadership |
Katie Vinter | Associate Director, Project Engineering | Leadership |
Philip Merksamer | Vp, Commercial Transactions & Business Development | Leadership |
Prabha Ramakrishnan | Senior Director, Business Development | Leadership |
216 more people are available in the full profile.
Complete people profiles for Ginkgo Bioworks
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ginkgo Bioworks
Ginkgo Bioworks is a publicly listed company on the NYSE with ticker symbol DNA in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Sep 2021
- Listed onNYSE: DNA
- Listed entityGinkgo Bioworks Holdings, Inc.
- Exchange sectorHealth services
- ISINUS37611X2099
- Share price$11.76 (-0.25% on the day) · 2026-10-13
- Market capitalisation$791.9M
- EPS (diluted, trailing year)$-5.44
- Volume (last session)1,864,099
Financials of Ginkgo Bioworks
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $170.2M | -$312.8M | -$255.1M |
| 2024 | $227.0M | -$547.0M | -$397.3M |
| 2023 | $251.5M | -$892.9M | -$600.7M |
| 2022 | $477.7M | -$2.10B | -$2.10B |
| 2021 | $313.8M | -$1.83B | -$1.80B |
Detailed financial statements for Ginkgo Bioworks
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ginkgo Bioworks
Ginkgo Bioworks has strategically engaged in corporate development activities, having acquired 12 companies. Notable acquisitions include Altar, Beacon Testing and Bitome.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene therapies for a broad range of diseases are developed. | patch.bio | New York, United States | 2020 | Feb 2024 | •••• | |
CRISPR-based COVID-19 molecular testing devices are manufactured. | proofdx.com | Cambridge, United States | 2020 | Feb 2024 | •••• | |
AI-based molecular modeling software is provided for drug design optimization. | reverielabs.com | Boston, United States | 2017 | Feb 2024 | •••• | |
Fluidic automated systems are developed for continuous microbial suspension culture. | altar.bio | Evry, France | 2017 | Oct 2022 | •••• | |
Tool to tune in-vivo to protein production | circularisbiotech.com | Davis, United States | 2004 | Oct 2022 | •••• | |
Provider of microbe-based diversified farm inputs | zymergen.com | Emeryville, United States | 2013 | Jul 2022 | •••• | |
Wearable device that tracks hydration levels | bitome.com | Boston, United States | 2016 | Jun 2022 | •••• | |
Using synthetic biology, non-GMO and directed evolution to engineer proteins, pathways and cells | fgen.ch | Basel, Switzerland | 2010 | Mar 2022 | •••• | |
Organizations are supported in scaling COVID-19 testing operations. | beacontesting.com | United States | 2020 | Jan 2022 | •••• | |
CRO focused on drug research & development services for molecular biology and fermentation products | ddna-biotech.com | Utrecht, Netherlands | 2015 | May 2021 | •••• |
Complete acquisition details for Ginkgo Bioworks
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Ginkgo Bioworks
15 dated milestones of Ginkgo Bioworks across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Ginkgo Bioworks is founded.
- Funding First funding round of $100K.
- Milestone Reaches Unicorn status.
- Acquisition Acquires Dutch DNA Biotech.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Beacon Testing.
- Acquisition Acquires FGen.
- Acquisition Acquires Bitome.
- Acquisition Acquires Zymergen.
- Acquisition Acquires Circularis.
- Acquisition Acquires Altar.
- Funding Latest funding round, Grant,.
- Acquisition Acquires Patch.
- Acquisition Acquires Proof Diagnostics.
- Acquisition Acquires Reverie Labs.
Competitors of Ginkgo Bioworks
Ginkgo Bioworks has 3 listed competitors in our database, 3 of them funded. They include Amyris, Pivot Bio and Asimov.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| pivotbio.com | 2010 | Berkeley, United States | $618.08M | 256 | Nitrogen-fixing microbes for corn crop nutrition are developed and applied. | |
| asimov.com | 2017 | Boston, United States | $209.4M | 87 | Provider of integrated suite for advanced genetic design and manufacturing |
Detailed competitors of Ginkgo Bioworks
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ginkgo Bioworks
The website of Ginkgo Bioworks (ginkgobioworks.com) receives about 10.8K visits a month.
- Monthly visits10.8K
▲ 96.5% vs previous month
Websites whose visitors overlap most with Ginkgo Bioworks. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| kerafast.com | 100% | 27.6K | #1,254,905 | View details | |
synberc.org | synberc.org | 83% | – | ||
dna20.com | dna20.com | 83% | – | ||
| invitrogen.com | 83% | 5.2K | #3,688,642 | View details | |
neb.uk.com | neb.uk.com | 78% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Ginkgo Bioworks
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Ginkgo Bioworks (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ginkgo Bioworks
Complete news archive for Ginkgo Bioworks
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ginkgo Bioworks
Ginkgo Bioworks was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Ginkgo Bioworks is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Jason Kelly is the CEO of Ginkgo Bioworks, as recorded in our data. They have also founded this company.
Ginkgo Bioworks is a funded company, having raised a total of $795.75M across 23 funding rounds to date. The company's 1st funding round was a Grant of $180K, raised on Jun 2009.
Ginkgo Bioworks has 638 employees.
Annual revenue of Ginkgo Bioworks is $170.16M as on Dec 31, 2025.
Ginkgo Bioworks was founded in 2008 in Boston, United States. Operations focus on the biotechnology sector, where gene editing technologies are applied to develop cultured ingredients for agriculture. Microbes are engineered and produced to create products including flavors, fragrances, cosmetics, and sweeteners. Services extend to supporting industrial applications through synthetic biology methods.
Ginkgo Bioworks offers AI Models, Data Generation, and Lab Automation.
Yes, Ginkgo Bioworks is publicly traded on NYSE under the ticker symbol DNA.
Ginkgo Bioworks has made 12 acquisitions, including Altar, Beacon Testing, and Bitome.
Ginkgo Bioworks has 50 investors. Key investors include Illumina, Gates, T. Rowe Price, General Atlantic, and Gates Foundation.